Novo Nordisk Acquires Akero Therapeutics for $5.2 Billion, Securing Key MASH Treatment EFX

Novo Nordisk has agreed to acquire clinical-stage Akero Therapeutics for up to $5.2 billion to integrate efruxifermin (EFX), a promising late-stage treatment for MASH, complementing Novo Nordisk's leadership in cardiometabolic disease.